12Jul 2023
A model‐based approach to predict individual weight loss with semaglutide in people with overweight or obesity

A model‐based approach to predict individual weight loss with semaglutide in people with overweight or obesity

The study analyzed data from three trials involving individuals with overweight or obesity, with or without type 2 diabetes, who received semaglutide treatment. The study developed a population pharmacokinetic model to describe semaglutide exposure and an exposure-response model to predict weight change. The results showed that exposure levels consistently explained weight-loss patterns across different trials and dosing regimens. The study concluded that the exposure-response model effectively predicts weight-loss trajectories for people receiving semaglutide doses of up to 2.4 mg once weekly.

  • #endo-diabetology

Like

Save

Share